Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock?

Company Overview - Ginkgo Bioworks Holdings, Inc. (DNA) shares increased by 18.9% to close at $11.25, with a notable trading volume compared to typical sessions, and a total gain of 36.1% over the past four weeks [1][2] Investor Sentiment - The surge in stock price is linked to positive investor expectations regarding Ginkgo's proprietary cell programming platforms, Foundry and Codebase, which are utilized in R&D services under collaboration and license agreements [2] Financial Performance Expectations - The company is projected to report a quarterly loss of $1.44 per share, reflecting a year-over-year increase of 55%, while revenues are expected to be $43 million, down 23.5% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 12.1% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - Ginkgo Bioworks is part of the Zacks Medical - Biomedical and Genetics industry, where Novavax (NVAX) has seen a decline of 1.1% to $6.3, with a return of -13.2% over the past month [5] - Novavax's consensus EPS estimate has decreased by 46.9% over the past month to -$0.12, representing a year-over-year change of -112.1% [6]